S‐phase fraction in superficial urothelial carcinoma of the bladder
A prospective, long‐term, follow‐up study

References

• Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083–6.
   PubMed Web of Science ®Google Scholar
• Kurth KH, Denis L, Bouffioux CH, et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 1995; 31A: 1840–6.
   PubMed Web of Science ®Google Scholar
• Larsson P. Wijkstrom H, Thorstenson A, Adolfsson J, Norming U, Wiklund P. et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003; 37: 195–201.
   PubMedGoogle Scholar
• Zieger K, Wolf H, Olsen PR, et al. Long term survival of patients with bladder tumors: the significance of risk factors. Br J Urol 1998; 82: 667–72.
   PubMedGoogle Scholar
• Neulander E, Kaneti J, Chaimovitz C, et al. Deoxy-ribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer. J Urol 1997; 157: 1254–9.
   PubMed Web of Science ®Google Scholar
• Blomjous ECM, Schipper NW, Book JP, et al. The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinomas. Am J Clin Pathol 1989; 91: 243–8.
   PubMed Web of Science ®Google Scholar
• Tribukait B. Flow cytometry in assessing the clinical aggressiveness of genitourinary neoplasm. World J Urol 1987; 5: 108–22.
   Web of Science ®Google Scholar
• Wheeless LL, Badalament RA, deVere White R, et al. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 1993; 14: 478–81.
   PubMedGoogle Scholar
• Harmer MH. Classification of malignant tumors, 3rd ed. Geneva, Switzerland: UICC; 1978. p. 113–7.
   Google Scholar
• Mostofi KF, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. In: International histological classification of tumors, No. 10. Geneva, Switzerland: WHO; 1973.
   Google Scholar
• Baisch H, Gödhe W, Linden WA. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 1975; 12: 31–9.
   PubMed Web of Science ®Google Scholar
• Allard P. Fradet PB, Tétu B. The early clinical course of primary Ta and Ti bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692–8.
   Google Scholar
• Masters JRW, Camplejohn RS, Parkinson MC, et al. DNA ploidy and the prognosis of stage pT1 bladder cancer. Br J Urol 1989; 64: 403–8.
   PubMedGoogle Scholar
• deVere White R, Deitch A, Daneshmand S, et al. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. Eur Urol 2000; 37: 595–600.
   PubMed Web of Science ®Google Scholar
• Strang P. Stendahl U, Tribukait B. Prognostic sig-nificance of S-phase fraction as measured by DNA flow cytometry in gynecologic malignancies. Ann N Y Acad Sci 1993; 677: 354–63.
   Google Scholar
• Pfister C, Lacombe L, Vezina M, et al. Prognostic value of the proliferative index determined by Ki67 immunostaining in superficial bladder tumors. Hum Pathol 1999; 30: 1350–5.
   PubMed Web of Science ®Google Scholar
• Lipponen PK, Eskelinen MJ, Jauhiainen K, et al. Proliferation indices as independent prognostic factors in papillary Ta-Ti transitional cell bladder tumors. Br J Urol 1993; 72: 451–7.
   PubMedGoogle Scholar
• Tachibana M, Miyakawa A, Miyakawa M, et al. Prognostic significance of flow cytometric deoxyribo-nucleic acid analysis for patients with superficial bladder cancers: a long-term follow-up study. Cancer Detect Prey 1999; 23: 155–62.
   PubMedGoogle Scholar
• Asakura T, Takano Y, Iki M, et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 1997; 158: 385–8.
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Rajala P. Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index, and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999; 36: 393–400.
   PubMed Web of Science ®Google Scholar
• Blanchet P. Droupy S, Eschwege P. et al. Prospective evaluation of Ki67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma. Eur Urol 2001; 40: 169–75.
   PubMed Web of Science ®Google Scholar
• Oosterhuis W, Schapers R, Janssen-Heijnen M, et al. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 2000; 88: 1598–605.
   Google Scholar
• Grossman HB, Liebert M, Antelo M, et al. P53 and Rb expression predict progression in Ti bladder cancer. Clin Cancer Res 1998; 4: 829–34.
   PubMed Web of Science ®Google Scholar
• Bol M, Book J, Rep S, et al. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial carcinomas of the urinary bladder. Urology 2002; 60: 1124–30.
   PubMed Web of Science ®Google Scholar
• Kiemeney LALM, Witjes JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60–4.
   PubMed Web of Science ®Google Scholar
• Kaubisch S, Lum B, Reese J, et al. Stage Ti bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28–31.
   PubMed Web of Science ®Google Scholar
• Mostofi FK, Davies CJ, Sesterhenn IA. Histological typing of urinary bladder tumors. In: International classification of tumors, No. 10, 2nd ed. Geneva, Switzerland: WHO; 1999.
   Google Scholar
• Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumors based on the cellular pattern. Preliminary report of a clinico-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965; 130: 371–8.
   Google Scholar